European journal of rheumatology最新文献

{"title":"Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study.","authors":"Elif Durak Ediboğlu, Muhammed Çınar, Didem Kozacı, Dilek Solmaz, Gökhan Sargın, Ömer Karadağ, Gülay Kınıklı, Umut Kalyoncu, Sedat Yılmaz, Taşkın Şentürk, Gökhan Kabadayı, Gökhan Keser, Gülen Hatemi, Kübra Kaya, Mustafa Özmen, Figen Yargucu, Yeşim Özgüler, Ayşe Cefle, Önay Gerçik, Bünyamin Kısacık, Servet Akar","doi":"10.5152/eurjrheum.2024.24013","DOIUrl":"10.5152/eurjrheum.2024.24013","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA).</p><p><strong>Methods: </strong>Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE).</p><p><strong>Results: </strong>A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb.</p><p><strong>Conclusion: </strong>The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"364-370"},"PeriodicalIF":16.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bullous Cutaneous Lupus Erythematosus and Class V Lupus Nephritis: Rare Concurrence.","authors":"Gauri Gaur, Pallavi Srivastava, Anukriti Subhagya, Kiran Preet Malhotra, Swastika Suvirya, Namrata Rao","doi":"10.5152/eurjrheum.2024.23058","DOIUrl":"10.5152/eurjrheum.2024.23058","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Rheumatologists' Teledermatology Practices and Perspectives.","authors":"Gökçe Kenar-Artın","doi":"10.5152/eurjrheum.2024.24044","DOIUrl":"10.5152/eurjrheum.2024.24044","url":null,"abstract":"<p><strong>Objective: </strong>In their regular practice, rheumatologists often come across patients with skin and nail abnormalities, so they need dermatology consultations. A new option available today is the use of telemedicine for dermatology consultations. The aim of this study is to assess how frequently rheumatologists use this method, known as teledermatology (TD), and to investigate their perspectives.</p><p><strong>Methods: </strong>This study is a survey of rheumatologists in Türkiye. The survey, generated with Google Docs, was e-mailed to rheumatologists who are members of the Turkish Rheumatology Association and asked them to complete it.</p><p><strong>Results: </strong>A total of 122 rheumatologists completed the survey, with 85 women (70%) and 37 men (30%). The rheumatologists claimed that they encounter a mean of 6.60 (SD: 6.90) patients with skin/ nail lesions each week in their clinical practice and consult them for face-to-face (FTF) dermatology examinations for a mean of 12.3 (SD: 15.56) patients every month. Of the rheumatologists who took part in the trial, 38.5% said they experienced the TD approach. Most of them (n: 30, 62.5%) use TD “occasionally.” A significant proportion of rheumatologists stated that they used TD to consult with dermatologists in their personal networks (54.2%), dermatologists at the hospital where they work (47.2%), or dermatologists with advanced academic training in their field (45.8%). Most rheumatologists (60.8%) reported that, following TD, they only refer their patients to FTF examinations if the dermatologist requests it (e.g., for a biopsy). Some of the rheumatologists (37.5%) stated that TD would be effective in all skin lesions, but most rheumatologists (52.1%) stated TD would be more beneficial for special skin/nail lesions like infectious skin lesions or inflammatory dermatoses.</p><p><strong>Conclusion: </strong>This study showed that a considerable number of rheumatologists use TD. Most rheumatologists schedule TD consults with dermatologists to gain speed for diagnosis and due to a lack of appointment availability from dermatologists. In rheumatology practice, clinicians have noted that they found TD effective for a wide range of skin/nail lesions.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"358-363"},"PeriodicalIF":16.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison and Significance of Contrast-Enhanced Computed Tomographic Findings of Large-Vessel Vasculitis Before and After Treatment: Differences Between Takayasu Arteritis and Giant Cell Arteritis.","authors":"Daiki Nakagomi, Tatsuya Shimizu, Shunsuke Furuta, Takahiro Sugiyama, Kei Kobayashi, Yoshiaki Kobayashi, Shunichiro Hanai, Kimie Harama, Takeyuki Kanzaki, Chisaki Ajima, Takao Sugiyama, Hiroshi Onishi, Hiroshi Nakajima","doi":"10.5152/eurjrheum.2024.24056","DOIUrl":"10.5152/eurjrheum.2024.24056","url":null,"abstract":"<p><strong>Objective: </strong>Imaging is essential for diagnosing large-vessel vasculitis (LVV). During diagnostic imaging, assessing disease activity and vascular damage separately is important. Acute-phase findings represent disease activity, while chronic-phase findings represent vascular damage; however, whether the imaging findings are acute or chronic may be unclear. We investigated how vascular lesions change before and after treatment and whether they were acute- or chronic-phase findings.</p><p><strong>Methods: </strong>Fifty-one patients with LVV who had undergone contrast-enhanced computed tomography (CT) scans from the neck to the pelvis before treatment and 1-4 months after treatment were recruited. Wall thickening, wall contrast enhancement, stenosis, occlusion, dilation, aneurysm, and calcification were semi-quantitatively assessed in 21 vessels from the common carotid to the common iliac artery.</p><p><strong>Results: </strong>Twenty-four patients were diagnosed with Takayasu arteritis (TAK), and 27 with giant cell arteritis (GCA). Wall thickening and wall contrast enhancement improved after the treatment, which was especially significant in the GCA group. No significant differences in stenosis, occlusion, dilation, aneurysm, or calcification were observed before and after treatment. Stenosis and occlusion were more common with TAK, while calcification was more common with GCA.</p><p><strong>Conclusion: </strong>Wall thickening and wall contrast enhancement are acute-phase findings (activity), while stenosis, occlusion, dilation, aneurysm, and calcification are chronic-phase findings (damage). The frequencies of these findings differ between TAK and GCA.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"371-377"},"PeriodicalIF":16.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Corticosteroid Use in Rheumatoid Arthritis Associated with a Rare Complication: Bilateral Tibial Plateau Osteonecrosis.","authors":"Ceyhun Bicilioğlu, İlhan Celil Özbek","doi":"10.5152/eurjrheum.2024.24033","DOIUrl":"10.5152/eurjrheum.2024.24033","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"388-389"},"PeriodicalIF":16.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homeopathy for Rheumatological Diseases: A Systematic Review.","authors":"Jozélio Freire de Carvalho, Aaron Lerner, Carina Benzvi","doi":"10.5152/eurjrheum.2024.23123","DOIUrl":"10.5152/eurjrheum.2024.23123","url":null,"abstract":"<p><p>Homeopathy has mainly been used to treat several diseases. On the other hand, it has been used in a few rheumatic disorders. The aim of this article is to review the use of homeopathy in rheumatic diseases (RDs). PubMed and Embase databases were examined for literature on homeopathy and RDs between 1966 and April 2023. There are 15 articles found with 811 patients. The diseases treated were osteoarthritis (n=3), followed by rheumatoid arthritis (n=3), ankylosing spondylitis (n=1), hyperuricemia (n=1), and tendinopathy (n=1). Age varied from 31 to 87 years old, and male gender ranged from 56.7% to 100%. Homeopathy changed from a fixed medicine to an individualized homeopathy. Most studies (9/15) demonstrated improvements after homeopathy. Side effects were not seen or minimal and were comparable to placebo groups. In conclusion, this review shows homeopathy is a promising and safe therapy for RD treatment. However, the data needs to be reproduced in future more extensive studies, including other rheumatic conditions.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"378-384"},"PeriodicalIF":16.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound in Rheumatology, It is a Must.","authors":"Hèctor Corominas, Fadi Badlissi","doi":"10.5152/eurjrheum.2024.250324","DOIUrl":"10.5152/eurjrheum.2024.250324","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"S275-S276"},"PeriodicalIF":1.3,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose Cyclophosphamide Without Stem Cell Rescue in Autoimmune Diseases: A Systematic Review.","authors":"Jozélio Freire de Carvalho, Thelma L Skare","doi":"10.5152/eurjrheum.2024.23104","DOIUrl":"https://doi.org/10.5152/eurjrheum.2024.23104","url":null,"abstract":"<p><p>High-dose cyclophosphamide without stem cell rescue is a radical therapy for refractory autoimmune diseases. The objective was to review the results of high-dose cyclophosphamide without stem cell rescue in autoimmune diseases. PubMed, Scielo, and Embase databases were systematically searched for articles on high-dose cyclophosphamide without stem cell rescue treating autoimmune diseases between 1966 and September 2022. Twenty-nine studies were identified, including a total of 404 patients. The diseases most studied were systemic lupus erythematosus (n=113), multiple sclerosis (n=99), aplastic anemia (n=86), and myasthenia gravis (n=33). Most authors used the posology of 50mg/kg/day over four days of cyclophosphamide associated with Mesna, prophylactic antibiotics, G-CSF (granulocyte colony-stimulating factor), and support of red blood cells, and platelet transfusion. The most common side effects were febrile neutropenia, alopecia, and gastrointestinal complaints. Regarding outcomes, most of the studies demonstrated improvement of the underlying autoimmune disease, some long-lived, but relapses and failures were also identified. In conclusion, high-dose cyclophosphamide without stem cell rescue is an effective option for treating severe autoimmune diseases. This procedure is relatively safe when the appropriate supportive care measures are taken.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 2","pages":"53-63"},"PeriodicalIF":1.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Phenotypes of Giant Cell Arteritis: Insights into Complications and Survival Outcomes.","authors":"Paula Estrada, Javier Narváez, Patricia Moya, Daniel Roig-Vilaseca, Oscar Camacho, Vanessa Navarro, Sergi Heredia, Dacia Cerdà, Delia Reina, Hèctor Corominas","doi":"10.5152/eurjrheum.2024.23065","DOIUrl":"https://doi.org/10.5152/eurjrheum.2024.23065","url":null,"abstract":"<p><strong>Background: </strong>Giant cell arteritis (GCA) is a heterogeneous disease with diverse clinical presentations and varying degrees of severity. This study aimed to assess the incidence of 3 clinical subsets in GCA and analyze associated severe complications and survival rates. By identifying distinct clinical patterns, the goal is to customize treatment approaches and minimize severe complications during follow-up.</p><p><strong>Methods: </strong>This retrospective study classified clinical manifestations of GCA into 3 major phenotypes based on the reason for consultation: i) cranial, ii) extracranial, and iii) occult GCA. These groups were analyzed and compared for acute complications, including severe ischemic complications, \"true\" occlusive disease, and late complications such as aortic aneurysm. Survival data were also collected during follow-up.</p><p><strong>Results: </strong>Visual disturbances were more common in the cranial GCA group compared to other subsets (P < .001). Blindness and stroke showed a clinically relevant trend, although statistical differences were not significant between the cranial GCA groups. Limb claudication was significantly more prevalent in the extracranial subset compared to the cranial or occult GCA subsets (12% vs. 2.6% vs. 0% respectively). Severe ischemic complications and true occlusive disease were more frequent in the cranial GCA groups (60%, P=.005 and 40%, P=1.64 respectively). Regarding mortality, there were no statistically significant differences in survival among the different clinical subsets. However, the occult GCA subset showed a trend towards a higher prevalence of deaths, both overall and specifically due to GCA.</p><p><strong>Conclusion: </strong>Clinical subsets in GCA present distinct complications and survival outcomes, with the cranial subset showing a higher incidence of severe ischemic events and the occult subset associated with delayed diagnosis and increased mortality. Recognizing these subsets is crucial for tailored treatment approaches and improving patient prognosis. Further prospective studies are needed to refine diagnostic and therapeutic strategies.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 2","pages":"33-38"},"PeriodicalIF":1.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Turkish Version of Spondyloarthritis Knowledge Questionnaire: A Methodological Study.","authors":"Öznur Erbay Dallı, Seda Pehlivan, Tuğba Ocak, Arzu Ceyhan, Yavuz Pehlivan","doi":"10.5152/eurjrheum.2024.24005","DOIUrl":"https://doi.org/10.5152/eurjrheum.2024.24005","url":null,"abstract":"<p><strong>Background: </strong>Information and education are recommended for patients with inflammatory arthritis including spondyloarthritis (SpA). However, there is no Turkish instrument available to measure the knowledge level of patients with SpA. The study aimed to translate the Spondyloarthritis Knowledge Questionnaire (SPAKE) into Turkish and investigate its validity and reliability.</p><p><strong>Methods: </strong>This methodological study was conducted between February 2023 and August 2023 in patients with SpA. Data were collected using the \"Patient Characteristics Form\" and the \"Turkish version of SPAKE (SPAKE-T).\" Language, content, item analysis, known-group technique, test-retest, and internal consistency were used to evaluate validity and reliability.</p><p><strong>Results: </strong>A total of 226 SpA patients participated in the study. The validity and reliability analysis of SPAKE-T showed the following results: (a) content validity index at item level between 0.86 and 1.00, (b) significant correlation between the total score of the questionnaire and its sub domains between 0.18 and 0.81 (P < .05), (c) item difficulty between 0.11 and 0.91, (d) item discrimination index between 0.26 and 0.81, (e) within the known group validity, significantly lower knowledge scores in patient groups with low education level, disease duration less than 10 years, and patients who did not receive education about their disease (P < .05), (f ) Cronbach alpha value was 0.80, and (g) test-retest reliability was 0.81.</p><p><strong>Conclusion: </strong>This study indicates that the SPAKE-T, which has satisfactory psychometric properties, can be easily used to assess the overall knowledge level of patients with SpA about disease self-management.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 2","pages":"39-45"},"PeriodicalIF":1.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}